Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR0302Base gel in nonsegmental vitiligo
NCT06790862Phase 2Active, not recruiting
- Sponsor
- Hengrui
- Start
- Feb 2025
- Primary completion
- Mar 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ivarmacitinib in Vitiligo, sponsored by Hengrui. Started Feb 2025; status: active, not recruiting.
02
Drugs
ivarmacitinib
03
Conditions
Vitiligo
Beyond the preview
Go deeper on NCT06790862.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06790862.